Garcia-Serra Allie, Amdur Robert J, Morris Christopher G, Mazzaferri Ernest, Mendenhall William M
Department of Radiation Oncology, University of Florida, College of Medicine, Gainesville, FL 32610-0385, USA.
Am J Clin Oncol. 2005 Jun;28(3):255-8. doi: 10.1097/01.coc.0000145985.64640.ac.
The purpose of this study was to determine whether the incidence of hypothyroidism following radiotherapy (RT) to the low neck is high enough to justify the routine monitoring of thyroid function in asymptomatic patients. A retrospective study of 504 patients with head and neck cancer whose RT fields included the thyroid gland was conducted. Patients were treated either with definitive or postoperative RT. Hypothyroidism was defined as a thyroid stimulating hormone (TSH) level > or =4.5 mIU/L, regardless of whether the patient had clinical symptoms. Of the 504 total patients, 206 had a serum TSH level checked at some point posttreatment. If we assume that patients who had no data did not have hypothyroidism, the actuarial freedom from hypothyroidism in the entire group was 78% at 5 years and 51% at 10 years. Of the 206 patients who had a documented posttreatment TSH, the actuarial freedom from hypothyroidism was 58% at 5 years and 26% at 10 years. Univariate analysis and multivariate analysis confirmed treatment modality to be a significant predictive factor. Definitive initial surgery that removed part of the thyroid gland increased the risk of developing hypothyroidism. Overall stage was also predictive on multivariate analysis. Head and neck irradiation results in biochemical hypothyroidism in at least 50% of patients. Thyroid function should be tested on a regular basis following RT to the low-neck region. Serum TSH should be checked every 6 months for the first 5 years and yearly thereafter. Thyroid hormone replacement should be initiated in any patient with a TSH of more than 4.5 mIU/L.
本研究的目的是确定低颈部放疗(RT)后甲状腺功能减退症的发生率是否高到足以证明对无症状患者进行甲状腺功能的常规监测是合理的。对504例头颈部癌患者进行了回顾性研究,这些患者的放疗野包括甲状腺。患者接受了根治性放疗或术后放疗。甲状腺功能减退症的定义为促甲状腺激素(TSH)水平≥4.5 mIU/L,无论患者是否有临床症状。在504例患者中,206例在治疗后的某个时间点检查了血清TSH水平。如果我们假设没有数据的患者没有甲状腺功能减退症,那么整个组在5年时无甲状腺功能减退症的精算自由度为78%,在10年时为51%。在206例有记录的治疗后TSH的患者中,5年时无甲状腺功能减退症的精算自由度为58%,10年时为26%。单因素分析和多因素分析证实治疗方式是一个显著的预测因素。切除部分甲状腺的根治性初始手术增加了发生甲状腺功能减退症的风险。多因素分析显示总体分期也具有预测性。头颈部放疗至少会导致50%的患者出现生化性甲状腺功能减退。对低颈部区域放疗后应定期检测甲状腺功能。在最初5年应每6个月检查一次血清TSH,此后每年检查一次。TSH超过4.5 mIU/L的任何患者都应开始甲状腺激素替代治疗。